Significant advances are being made in the treatment of depression in children and adolescents. In a relatively short period, we have moved away from whether or not children get depressed to how to develop a comprehensive treatment strategy for depression in children and adolescents. It is expected that the increase in the understanding of the psychopharmacologic management of depression in children and adolescents will be greatly enhanced by the collaborative arrangements between universities, the National Institute of Mental Health, the Food and Drug Administration, and the pharmaceutical industry. Recent changes in federal regulations have greatly enhanced the amount of research being conducted in the pediatric age group. Although research into psychopharmacologic treatment of acute depression has increased, there remain many areas in need of further research, including continuation and maintenance treatment and treatment-resistant depression. The integration of psychotherapy and psychopharmacology and the increase in effectiveness trials, which assess outcomes in addition to symptom change (such as social and family functioning and economic changes) are needed.
ASJC Scopus subject areas
- Psychiatry and Mental health